Literature DB >> 20672374

Experience with carrier screening and prenatal diagnosis for 16 Ashkenazi Jewish genetic diseases.

Stuart A Scott1, Lisa Edelmann, Liu Liu, Minjie Luo, Robert J Desnick, Ruth Kornreich.   

Abstract

The success of prenatal carrier screening as a disease prevention strategy in the Ashkenazi Jewish (AJ) population has driven the expansion of screening panels as disease-causing founder mutations have been identified. However, the carrier frequencies of many of these mutations have not been reported in large AJ cohorts. We determined the carrier frequencies of over 100 mutations for 16 recessive disorders in the New York metropolitan area AJ population. Among the 100% AJ-descended individuals, screening for 16 disorders resulted in ∼1 in 3.3 being a carrier for one disease and ∼1 in 24 for two diseases. The carrier frequencies ranged from 0.066 (1 in 15.2; Gaucher disease) to 0.006 (1 in 168; nemaline myopathy), which averaged ∼15% higher than those for all screenees. Importantly, over 95% of screenees chose to be screened for all possible AJ diseases, including disorders with lower carrier frequencies and/or detectability. Carrier screening also identified rare individuals homozygous for disease-causing mutations who had previously unrecognized clinical manifestations. Additionally, prenatal testing results and experience for all 16 disorders (n = 574) are reported. Together, these data indicate the general acceptance, carrier frequencies, and prenatal testing results for an expanded panel of 16 diseases in the AJ population.
© 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2010        PMID: 20672374      PMCID: PMC2970726          DOI: 10.1002/humu.21327

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  59 in total

Review 1.  Niemann-Pick disease: mutation update, genotype/phenotype correlations, and prospects for genetic testing.

Authors:  E H Schuchman; S R Miranda
Journal:  Genet Test       Date:  1997

2.  High frequency of a common Bloom syndrome Ashkenazi mutation among Jews of Polish origin.

Authors:  L Shahrabani-Gargir; R Shomrat; Y Yaron; A Orr-Urtreger; J Groden; C Legum
Journal:  Genet Test       Date:  1998

3.  Carrier frequency of the Bloom syndrome blmAsh mutation in the Ashkenazi Jewish population.

Authors:  L Li; C Eng; R J Desnick; J German; N A Ellis
Journal:  Mol Genet Metab       Date:  1998-08       Impact factor: 4.797

4.  Prevalence of glucocerebrosidase mutations in the Israeli Ashkenazi Jewish population.

Authors:  M Horowitz; M Pasmanik-Chor; Z Borochowitz; T Falik-Zaccai; K Heldmann; R Carmi; R Parvari; H Beit-Or; B Goldman; L Peleg; E Levy-Lahad; P Renbaum; S Legum; R Shomrat; H Yeger; D Benbenisti; R Navon; V Dror; M Shohat; N Magal; N Navot; N Eyal
Journal:  Hum Mutat       Date:  1998       Impact factor: 4.878

5.  Molecular basis of lipoamide dehydrogenase deficiency in Ashkenazi Jews.

Authors:  A Shaag; A Saada; I Berger; H Mandel; A Joseph; A Feigenbaum; O N Elpeleg
Journal:  Am J Med Genet       Date:  1999-01-15

6.  Cystic fibrosis heterozygote screening in the Orthodox Community of Ashkenazi Jews: the Dor Yesharim approach and heterozygote frequency.

Authors:  D Abeliovich; A Quint; N Weinberg; G Verchezon; I Lerer; J Ekstein; E Rubinstein
Journal:  Eur J Hum Genet       Date:  1996       Impact factor: 4.246

Review 7.  Molecular diagnosis of inherited disorders: lessons from hemoglobinopathies.

Authors:  George P Patrinos; Panagoula Kollia; Manoussos N Papadakis
Journal:  Hum Mutat       Date:  2005-11       Impact factor: 4.878

8.  Increased risk of idiopathic chronic pancreatitis in cystic fibrosis carriers.

Authors:  Jonathan A Cohn; John P Neoptolemos; Jinong Feng; Jin Yan; Zefei Jiang; William Greenhalf; Christopher McFaul; Roger Mountford; Steve S Sommer
Journal:  Hum Mutat       Date:  2005-10       Impact factor: 4.878

9.  The frequency of mucolipidosis type IV in the Ashkenazi Jewish population and the identification of 3 novel MCOLN1 mutations.

Authors:  Gideon Bach; Michael B T Webb; Ruth Bargal; Marcia Zeigler; Joseph Ekstein
Journal:  Hum Mutat       Date:  2005-12       Impact factor: 4.878

10.  Prenatal genetic carrier testing using triple disease screening.

Authors:  C M Eng; C Schechter; J Robinowitz; G Fulop; T Burgert; B Levy; R Zinberg; R J Desnick
Journal:  JAMA       Date:  1997-10-15       Impact factor: 56.272

View more
  53 in total

1.  Carrier screening in preconception consultation in primary care.

Authors:  Sylvia A Metcalfe
Journal:  J Community Genet       Date:  2011-12-20

2.  Identification of CYP2C19*4B: pharmacogenetic implications for drug metabolism including clopidogrel responsiveness.

Authors:  S A Scott; S Martis; I Peter; Y Kasai; R Kornreich; R J Desnick
Journal:  Pharmacogenomics J       Date:  2011-03-01       Impact factor: 3.550

3.  Platelet hexosaminidase a enzyme assay effectively detects carriers missed by targeted DNA mutation analysis.

Authors:  Sachiko Nakagawa; Jie Zhan; Wei Sun; Jose Carlos Ferreira; Steven Keiles; Tina Hambuch; Anja Kammesheidt; Brian L Mark; Adele Schneider; Susan Gross; Nicole Schreiber-Agus
Journal:  JIMD Rep       Date:  2012-01-31

Review 4.  The clinical management of Type 2 Gaucher disease.

Authors:  Karin Weiss; Ashley Gonzalez; Grisel Lopez; Leah Pedoeim; Catherine Groden; Ellen Sidransky
Journal:  Mol Genet Metab       Date:  2014-11-14       Impact factor: 4.797

5.  Integrated CYP2D6 interrogation for multiethnic copy number and tandem allele detection.

Authors:  Wanqiong Qiao; Suparna Martis; Geetu Mendiratta; Lisong Shi; Mariana R Botton; Yao Yang; Andrea Gaedigk; Raymon Vijzelaar; Lisa Edelmann; Ruth Kornreich; Robert J Desnick; Stuart A Scott
Journal:  Pharmacogenomics       Date:  2018-12-06       Impact factor: 2.533

6.  Evaluation of two-year Jewish genetic disease screening program in Atlanta: insight into community genetic screening approaches.

Authors:  Yunru Shao; Shuling Liu; Karen Grinzaid
Journal:  J Community Genet       Date:  2015-01-07

7.  Comprehensive population screening in the Ashkenazi Jewish population for recurrent disease-causing variants.

Authors:  L Shi; B D Webb; A H Birch; L Elkhoury; J McCarthy; X Cai; K Oishi; L Mehta; G A Diaz; L Edelmann; R Kornreich
Journal:  Clin Genet       Date:  2016-08-22       Impact factor: 4.438

8.  Knowledge, attitudes, and barriers to carrier screening for the Ashkenazi Jewish panel: a Florida experience : Education and Barriers assessment for Jewish Genetic Diseases.

Authors:  Jessica R L Warsch; Sean Warsch; Elizabeth Herman; Lauren Zakarin; Adele Schneider; Jodi Hoffman; Deborah Wasserman; Deborah Barbouth
Journal:  J Community Genet       Date:  2014-01-12

9.  Frequency of the cholesteryl ester storage disease common LIPA E8SJM mutation (c.894G>A) in various racial and ethnic groups.

Authors:  Stuart A Scott; Benny Liu; Irina Nazarenko; Suparna Martis; Julia Kozlitina; Yao Yang; Charina Ramirez; Yumi Kasai; Tommy Hyatt; Inga Peter; Robert J Desnick
Journal:  Hepatology       Date:  2013-07-29       Impact factor: 17.425

10.  The p.L302P mutation in the lysosomal enzyme gene SMPD1 is a risk factor for Parkinson disease.

Authors:  Ziv Gan-Or; Laurie J Ozelius; Anat Bar-Shira; Rachel Saunders-Pullman; Anat Mirelman; Ruth Kornreich; Mali Gana-Weisz; Deborah Raymond; Liron Rozenkrantz; Andres Deik; Tanya Gurevich; Susan J Gross; Nicole Schreiber-Agus; Nir Giladi; Susan B Bressman; Avi Orr-Urtreger
Journal:  Neurology       Date:  2013-03-27       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.